| Literature DB >> 35068933 |
Cindy Negrete-González1,2, Edgar Turrubiartes-Martínez2,3, Miriam Briano-Macias2, Daniel Noyola4, Luis Fernando Pérez-González5, Roberto González-Amaro6, Perla Niño-Moreno1,2.
Abstract
INTRODUCTION: Citrobacter spp. is an opportunistic bacteria that have been recognized as significant pathogens in patients with underlying diseases or immunocompromised status. The aim of this study was to identify extended-spectrum β-lactamases in clinical isolates of Citrobacter spp.Entities:
Keywords: CTX-M-15; Citrobacter; ESBL; PER-1; TEM; VEB-1; plasmid
Year: 2022 PMID: 35068933 PMCID: PMC8771733 DOI: 10.1177/11786337211065750
Source DB: PubMed Journal: Infect Dis (Auckl) ISSN: 1178-6337
Type of bacterial isolates from different clinical samples.
| Types of the specimens |
|
|
|
|
|---|---|---|---|---|
| N = 14 | N = 2 | N = 2 | N = 1 | |
| Skin and soft tissue | 11 | 1 | 0 | 1 |
| Urine | 2 | 0 | 2 | 0 |
| Blood | 1 | 1 | 0 | 0 |
Phenotypic and genotypic detection of ESBL for strains studied.
| Strain | Phenotypic confirmatory test of ESBL | |||||||
|---|---|---|---|---|---|---|---|---|
| CAZ/CAZ-CL (mm) | CTX/CTX-CL (mm) | Result | CTX-M | TEM | SHV | VEB-1 | PER-1 | |
| 18/24 | 11/24 | Positive | − | − | − | + | − | |
| 19/25 | 13/25 | Positive | + | + | − | − | − | |
| 10/13 | 10/13 | Negative | − | − | − | − | − | |
| 20/22 | 16/21 | Positive | + | + | − | + | + | |
Abbreviations: CAZ, Ceftazidime; CAZ/CL, Ceftazidime/Clavulanic acid; CTX, Cefotaxime; CTX/CL, Cefotaxime/Clavulanic acid.
Figure 1.Agarose gel electrophoresis for the PCR products of ESBL: (a) the blaTEM gene. Line M: 100 bp ladder, line 1: positive control, line 2: negative control, lines 3 and 6: R-086 and R-135 strains (blaTEM positive), lines 4 and 5 blaTEM negative strains, (b) the blaCTX-M gene. Line M: 100 bp ladder, line 1: negative control, line 2: positive control, lines 3 and 6: R-086 and R-135 strains (blaCTX-M positive), lines 4 and 5: R-099 and R-134 strains (blaCTX-M negative), (c) the blaVEB-1 gene. Line M: 100 bp ladder, line 1: negative control, line 2: positive control, lines 3 and 6: R-086 and R-134 strains (blaVEB-1 negative), lines 4 and 5: R-099 and R-135 strains (blaVEB-1 positive), and (d) the blaPER-1 gene. Line M: 100 bp ladder, line 1: negative control, line 2: positive control, line 5: R-135 strain (blaPER-1 positive), lines 3, 4, and 6: blaPER-1 negative strains.
Figure 2.Agarose gel electrophoresis for the PCR products of Top10R-135 strain: (a) the blaCTX-M-15 gene. Line M: 100 bp ladder, line 1: negative control, line 2: R-135 strain (blaCTX-M-15 positive), line 3: R-135p, line 4: Top10R-135 (transformant strain), and 5: E. coli Top-10, (b) the blaPER-1 gene. Line M: 100 bp ladder, line 1: negative control, line 2: R-135 strain (blaPER-1 positive), line 3: R-135p, line 4: Top10R-135 (transformant strain), and 5: E. coli Top-10, and (c) the blaTEM-1 gene. Line M: 100 bp ladder, line 1: negative control, line 2: R-135 strain (blaTEM positive), line 3: R-135p, line 4: Top10R-135 (transformant strain), and 5: E. coli Top-10.
Minimum inhibitory concentration (μg/mL).
| Antimicrobial | Breakpoints (CLSI) | |||
|---|---|---|---|---|
| Ampicillin | ⩾1024 | ⩾1024 | 8 | ⩾32 |
| Cephalotine | 1024 | ⩾1024 | 8 | ⩾32 |
| Ceftriaxone | 1024 | ⩾2048 | ⩽4 | ⩾4 |
| Ceftazidime | 32 | 32 | ⩽4 | ⩾16 |
| Meropenem | ⩽0.25 | ⩽0.25 | ⩽0.25 | ⩾4 |